Is there still a role for mTOR inhibitors in metastatic RCC in the immunotherapy/TKI era?

Practically all my patients with metastatic clear cell RCC will receive an mTOR inhibitor at some time during their treatment course unless they achieve durable CR with early therapy lines. It is a plausible pathway to target, often well tolerated, and very rarely (one in hundreds) may produce durable CRs in otherwise refractory subtypes. Typically prefer to combine with lenvatinib for extra push and then titrate each drug per side effect profile.

Our phase 2 multicenter lencabo RCT randomizing ...